Pharmaceutical marketing leaders do not need another isolated AI feature. They need a better operating model.

Across global pharma organizations, the pressure is clear: produce more content for more brands, more audiences, more channels and more markets—without increasing cost, risk or review burden. Healthcare professionals, patients and caregivers all expect communications that are timely, relevant and tailored to context. But in many enterprises, the content supply chain was not built for that level of personalization, localization or speed.

The result is a familiar pattern. Briefing happens in one place. Copy creation happens somewhere else. Imagery is managed in another system. Translation is routed through separate vendors. Medical, legal and brand review arrive late in the process. Local teams rebuild assets that already exist. Global teams struggle to maintain consistency. Every handoff adds time. Every market adaptation adds complexity. And every disconnected step reduces reuse, visibility and control.

For marketing operations and transformation leaders, this is the real issue. The challenge is not simply generating more assets. It is redesigning the end-to-end content supply chain so content can move from brief to activation through one governed, repeatable workflow.

Bodhi enables pharmaceutical organizations to move from fragmented, outsourced production toward a connected, AI-assisted operating layer for content operations. Instead of treating briefing, generation, localization, adaptation, approval and activation as separate tasks managed across disconnected teams and tools, Bodhi helps orchestrate them as one workflow built for enterprise scale, governance and throughput.

This matters because the biggest delays in pharma content operations rarely come from one task alone. They come from the gaps between tasks: waiting for rewrites, recreating approved assets for another channel, translating content after the fact, routing materials through disconnected review cycles or repurposing work manually for regional use. In highly regulated environments, those gaps are expensive. They slow time-to-market, increase operational drag and make personalization harder to scale.

With Bodhi, teams can connect the workflow from the start. A campaign or content brief can feed AI-assisted concepting, compliant-ready copy and imagery generation, campaign creation, localization, translation, asset repurposing and downstream preparation for deployment. Approved materials can be adapted across banners, emails, digital sales presentations and other formats without starting from scratch each time. Local teams can tailor for language, market context and channel needs while central teams maintain stronger governance, consistency and transparency.

Just as important, the workflow is designed for regulated reality. In pharma, speed only matters if it comes with control. Bodhi helps embed guardrails into content operations from the beginning rather than treating governance as a final checkpoint. That makes it easier to generate compliant-ready outputs, support human-in-the-loop review for high-stakes decisions and create clearer traceability across the content lifecycle. Marketing, compliance, IT and regional stakeholders gain a more shared, auditable foundation for how content is created, adapted and approved.

For large pharmaceutical enterprises, this is the difference between using AI as a speed tool and using AI to redesign operations.

Publicis Sapient brings that broader transformation lens. The work is not limited to deploying a model or automating a single content task. It is about redesigning how content moves across the organization—combining strategy, workflow design, data and AI, technology engineering and marketing platform integration to create a scalable system for global execution. That means helping enterprises connect content generation with the systems and controls they already rely on, so the solution becomes part of the operating model rather than another disconnected point solution.

Bodhi’s capabilities support this transformation across the full content lifecycle. Organizations can generate personalized copy and imagery, create end-to-end campaigns, recommend visuals, localize and translate content for regional replication, and repurpose assets across digital formats. Multimodal support across text and imagery helps teams create for cross-channel experiences more efficiently. Integration with enterprise environments helps organizations operationalize AI securely and at scale, including in client-hosted deployments where privacy, traceability and control are essential.

The impact of this model is already proven in pharmaceutical marketing. For a leading global pharmaceutical company, Publicis Sapient helped transform slow, manual and outsourced content operations into a more scalable AI-powered system for personalized marketing. The organization needed to support hundreds of brands and markets while meeting growing demand for localized, audience-specific messaging. With Bodhi-enabled workflows for generation, localization, translation, repurposing and campaign creation, the company achieved 75% faster content production, up to 45% cost reduction and faster time-to-market.

Those outcomes matter. But for transformation leaders, the deeper value is what they represent: a governed system for repeatable content throughput. A model that can support global replication without losing local relevance. A way to increase reuse, reduce manual effort and create more content variations without proportionally increasing operating cost or review burden.

This is especially important as pharmaceutical organizations scale across dozens of markets and increasingly diverse stakeholder groups. HCP communications are different from patient communications. Regional regulations differ. Channel requirements vary. Personalization expectations continue to rise. Without a connected supply chain, each new content variation adds more friction. With the right operating model, variation becomes manageable because it is built on reuse, orchestration and governance.

With Publicis Sapient and Sapient Bodhi, organizations can move beyond fragmented production and toward a governed, AI-assisted workflow that connects briefing, generation, adaptation, translation, approval and activation in one system. The result is not simply more content, faster. It is a stronger content operation—one that is more scalable, more reusable, more localized and better suited to the realities of regulated global growth.

For pharmaceutical marketing operations leaders, that is where real transformation happens: not in isolated content generation, but in building a repeatable, enterprise-ready engine for speed, control and personalization at scale.